Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

MLA

Toshifumi Hibi, et al. “Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Japanese Patients with Moderately to Severely Active Ulcerative Colitis: A Post-Hoc Analysis of the Phase 2b/3 SELECTION Trial.” Intestinal Research, vol. 21, no. 1, Jan. 2023, pp. 110–25. EBSCOhost, https://doi.org/10.5217/ir.2021.00143.

APA

Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, & Mamoru Watanabe. (2023). Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intestinal Research, 21(1), 110–125. https://doi.org/10.5217/ir.2021.00143

Chicago

Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, et al. 2023. “Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Japanese Patients with Moderately to Severely Active Ulcerative Colitis: A Post-Hoc Analysis of the Phase 2b/3 SELECTION Trial.” Intestinal Research 21 (1): 110–25. doi:10.5217/ir.2021.00143.